Narsoplimab is a clinical-stage drug being developed for the treatment of HSCT-TMA (Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy) is a life-threatening blood clotting disorder that occurs after stem cell transplants. It is driven by an overactivation of the complement system, a component of the innate immune response, which leads to endothelial injury, microvascular thrombosis and obstructs blood flow to vital organs such as the kidneys and lungs. This process destroys red blood cells, leading to severe anemia, bleeding complications, and ultimately multi‑organ failure. Reported incidence varies widely, ranging from 0.5% to 76% among transplant recipients, with an estimated prevalence of approximately 8.2% in this population. Median mortality reaches 75% without effective treatment (1). Around 23,000 HSCT is perform every year in US (2), which means that every year there is 1,886 patients will potentially developed HSCT-TMA. . It is being developed by Omeros Corporation. The FDA Prescription Drug User Fee Act (PDUFA) date is December 25, 2025. Premium analysis including detailed clinical trial status, revenue predictions, and comprehensive company insights are available for members.